Renata Murgasova1, Ester Tor Carreras2, Julien Bourgailh2. 1. PKS, Novartis Institute for Biomedical Research, Novartis Pharma AG, WSJ-153.1.16, 4002, Basel, Switzerland. renata.murgasova@novartis.com. 2. PKS, Novartis Institute for Biomedical Research, Novartis Pharma AG, WSJ-153.1.16, 4002, Basel, Switzerland.
Abstract
BACKGROUND AND OBJECTIVE: The present study was designed to validate the functional assay that enables rapid screening of therapeutic candidates for their effect on mitochondrial fatty acid oxidation. METHODS: The two whole-cell systems (tissue homogenates and hepatocytes) have been evaluated to monitor the total beta-oxidation flux of physiologically important 3H-palmitic acid by measurement of tritiated water enrichment in incubations using UPLC coupled on-line to radioactivity monitoring and mass spectrometry. RESULTS: Our results with several known inhibitors of fatty acid oxidation showed that this simple assay could correctly predict a potential in alteration of mitochondrial function by drug candidates. Since the beta-oxidation of palmitic acid takes place almost exclusively in mitochondria of human hepatocytes, this model can be also utilized to distinguish between the mitochondrial and peroxisomal routes of this essential metabolic pathway in some cases. CONCLUSIONS: The present work offers a new in vitro screen of changes in mitochondrial beta-oxidation by xenobiotics as well as a model to study the mechanism of this pathway.
BACKGROUND AND OBJECTIVE: The present study was designed to validate the functional assay that enables rapid screening of therapeutic candidates for their effect on mitochondrial fatty acid oxidation. METHODS: The two whole-cell systems (tissue homogenates and hepatocytes) have been evaluated to monitor the total beta-oxidation flux of physiologically important 3H-palmitic acid by measurement of tritiated water enrichment in incubations using UPLC coupled on-line to radioactivity monitoring and mass spectrometry. RESULTS: Our results with several known inhibitors of fatty acid oxidation showed that this simple assay could correctly predict a potential in alteration of mitochondrial function by drug candidates. Since the beta-oxidation of palmitic acid takes place almost exclusively in mitochondria of human hepatocytes, this model can be also utilized to distinguish between the mitochondrial and peroxisomal routes of this essential metabolic pathway in some cases. CONCLUSIONS: The present work offers a new in vitro screen of changes in mitochondrial beta-oxidation by xenobiotics as well as a model to study the mechanism of this pathway.
Authors: Cynthia Moffat; Lavesh Bhatia; Teresa Nguyen; Peter Lynch; Miao Wang; Dongning Wang; Olga R Ilkayeva; Xianlin Han; Matthew D Hirschey; Steven M Claypool; Erin L Seifert Journal: J Lipid Res Date: 2014-08-11 Impact factor: 5.922
Authors: Ola Westman; Maria Larsson; Nikolaos Venizelos; Henner Hollert; Magnus Engwall Journal: Environ Sci Pollut Res Int Date: 2014-01-03 Impact factor: 4.223
Authors: Ronald J A Wanders; Jos P N Ruiter; Lodewijk IJLst; Hans R Waterham; Sander M Houten Journal: J Inherit Metab Dis Date: 2010-05-20 Impact factor: 4.982
Authors: Fredrick T Harris; S M Jamshedur Rahman; Mohamed Hassanein; Jun Qian; Megan D Hoeksema; Heidi Chen; Rosana Eisenberg; Pierre Chaurand; Richard M Caprioli; Masakazu Shiota; Pierre P Massion Journal: Cancer Prev Res (Phila) Date: 2014-05-12
Authors: R S Kler; S Jackson; K Bartlett; L A Bindoff; S Eaton; M Pourfarzam; F E Frerman; S I Goodman; N J Watmough; D M Turnbull Journal: J Biol Chem Date: 1991-12-05 Impact factor: 5.157